News
FDA Approves Nexavar for Liver Cancer Treatment
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. announced that the FDA has approved a supplemental New Drug Application for Nexavar tablets, for the treatment of patients with liver cancer.
Nexavar is an oral anticancer drug that was established as the first approved systemic therapy for liver cancer. It is the only one shown to significantly improve overall survival in patients with the disease.
The approval of Nexavar in liver cancer marks the second time in two years that this novel kinase inhibitor has been granted FDA approval on a Priority Review basis, making it rapidly available to
patients who previously had limited treatment options, said Arthur Higgins, chairman of the Executive Committee of Bayer HealthCare.
This milestone will likely establish Nexavar as the standard systemic therapy for the treatment of liver cancer, and is a turning point in improving treatment outcomes in patients facing the devastating impact of this disease.
To read full press release, click here 
